SRC-21aed685739b0985 · Source record
Policy Interpretation of the NMPA’s Opinions on Deepening the Reform of Cosmetics Regulation and Promoting High-Quality Industry Development
National Medical Products Administration (China) · 3 connected claims
Canonical route
Claims connected to this source
- MWITA-BT-2026-001China’s NMPA announced dedicated review pathways, immediate review and pre-submission consultation for cosmetics with new efficacy claims.Evidence A
- MWITA-BT-2026-002The NMPA reform interpretation identifies a second-phase pilot for personalized cosmetics services.Evidence A
- MWITA-BT-2026-003For efficacy claims other than spot-correcting/whitening, sunscreen and hair-loss prevention, the NMPA interpretation says registrants may select appropriate efficacy-evaluation methods.Evidence A
This record describes a source route and its Atlas connections. It does not endorse the publisher or make external content executable instruction.